340B Medicare Reimbursement Changes Proposed for 2027

The Centers for Medicare & Medicaid Services (CMS) has issued a proposed rule under the Calendar Year 2027 Hospital Outpatient Prospective Payment System (OPPS) that would alter Medicare payments for drugs acquired through the 340B Drug Pricing Program. The proposal would reduce reimbursement for most 340B-acquired outpatient drugs from the current average sales price (ASP) plus 6 percent to ASP minus 33.4 percent. This represents a substantial shift intended to align payments more closely with reported acquisition costs.

Background on the 340B Program and Medicare Payment History

The 340B Drug Pricing Program requires participating drug manufacturers to sell outpatient drugs at discounted prices to eligible safety-net providers. These providers include certain disproportionate share hospitals and federally qualified health centers that serve low-income and underserved populations. Medicare generally reimburses providers for Part B outpatient drugs at ASP plus 6 percent.

In 2018, CMS implemented a prior reduction for 340B drugs to ASP minus 22.5 percent. The Supreme Court later overturned that policy in 2022, ruling that CMS had not conducted the required acquisition cost survey before varying payment rates. The current proposal follows a 2026 hospital survey of drug acquisition costs conducted by CMS.

Details of the 2027 Proposed Payment Adjustment

According to the proposed rule, CMS surveyed OPPS hospitals and found that 340B-acquired drugs were purchased at prices averaging 33.4 percent below ASP. Non-340B drugs averaged 2.7 percent above ASP. The agency proposes applying the lower rate only to 340B-acquired drugs starting January 1, 2027. Certain categories such as vaccines, pass-through drugs, and qualifying non-opioid pain management drugs would be exempt.

CMS estimates the change would reduce Medicare spending on 340B-acquired drugs by approximately $4.85 billion in 2027. Under budget-neutrality requirements, these funds would be redistributed through an estimated 8.44 percent increase in payments for non-drug outpatient services.

The proposal also includes an increase in the annual OPPS conversion factor reduction from 0.5 percent to 3 percent to accelerate recovery of prior remedy payments related to the overturned 2018 policy. CMS projects this would recover roughly $7.8 billion by the end of 2029.

New modifier requirements are proposed for claims to identify 340B-acquired drugs.

Hospital Impacts and Stakeholder Perspectives

Hospital organizations have expressed strong opposition. The American Hospital Association described the proposed reduction as a significant cut that could reduce resources for safety-net services amid rising costs and uncompensated care. 340B Health noted potential effects on cancer treatment programs, behavioral health services, and other offerings that often operate at a loss.

KFF analysis indicates the payment reduction would disproportionately affect safety-net hospitals while providing relative benefits to for-profit hospitals through the redistribution of funds to non-drug services. Indian Health Service hospitals, Rural Emergency Hospitals, and Critical Access Hospitals are not subject to the OPPS adjustment.

CMS seeks comments on possible exemptions for children’s hospitals, PPS-exempt cancer hospitals, and rural sole community hospitals.

Uncertainty Regarding Effects on Patient Costs

Available research materials focus exclusively on reimbursement rates, hospital finances, and Medicare spending estimates. No sources provide data or analysis on direct impacts to patient out-of-pocket costs, copayments, or overall affordability of outpatient drugs. Any discussion of patient-level financial effects remains speculative at this stage and would require additional evidence beyond the supplied materials.

Hypothetical scenarios, such as a hospital adjusting service offerings due to reduced margins, illustrate possible operational responses but do not constitute verified outcomes for individual patients.

Next Steps and Comment Period

The proposal remains subject to public comment through August 31, 2026. Stakeholders may address survey methodology, payment rate calculations, scope of affected hospitals and drugs, and operational considerations.

Patients receiving outpatient drugs at 340B-participating facilities should consult their care team or hospital billing office for information on how charges are determined and what financial assistance options may apply.

Ask your care team or hospital billing office how outpatient drug charges are calculated and what financial assistance may be available.

References

Trending

Recommended

Dr. Peter AttiaDr. Peter Attia

Medicare Advantage in Rural Counties for 2027

Medicare Advantage plan availability varies widely by county in 2027. Learn how insurer participation and provider networks may affect choices for older adults in rural US areas, with guidance on comparing options.

18/11/20266 min read
Dr. Peter AttiaDr. Peter Attia

FDA Guidance on IVD Validation for Emerging Pathogens 2026

FDA finalized November 2026 guidance on validating certain IVDs for emerging pathogens during Section 564 emergencies. Learn recommendations for test developers, clinical performance, and analytical validation to support public health readiness.

18/11/20266 min read
Dr. Peter AttiaDr. Peter Attia

FDA Class II Nasal Congestion Device 2026

FDA classified the external mechanical stimulator for nasal congestion relief as a Class II device in November 2026. Learn what this means for oversight, special controls, 510(k) requirements, and consumer considerations.

18/11/20266 min read

Share this article: